Patent eligibility of stem cells in Europe: where do we stand after 8 years of case law?-Reference-Cited by-同舟云学术

Patent eligibility of stem cells in Europe: where do we stand after 8 years of case law?

Published:2017-01 Issue:1 Volume:12 Page:37-51
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Storz Ulrich¹,Faltus Timo²

Affiliation:

1. Michalski ⋅ Hüttermann & Partner Patent Attorneys, Düsseldorf, Germany

2. Martin Luther University, Halle-Wittenberg, Germany, Faculty of Law, Economics and Business

Abstract

Since 2006, some of the highest ranking European Courts have issued decisions related to the patent eligibility of human embryonic stem cells. The question of patent eligibility of human embryonic stem cells remains, however, still erratic, at least in some aspects. This article will give a short comprehensive overview of the case history, and discuss questions still unsolved.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2016-0099

Reference31 articles.

1. The patentability of human embryonic stem cells in Europe

2. Principles of International Economic Law

3. European Patent Office. Patents and biotechnology – latest developments. http://blog.epo.org/uncategorized/patents-and-biotechnology-%E2%80%93-latest-developments/.

4. Rules 23b–23e under EPC 1973, now Rules 26 – 29.

5. Like Switzerland, Turkey or Norway. www.epo.org/about-us/organisation/member-states.html.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point;Biotechnology Law Report;2024-02-01

2. The Regulation of Human Germline Genome Modification in Germany;Human Germline Genome Modification and the Right to Science;2020-01-31